Shopping Cart 0
Cart Subtotal
USD 0

Multiple Sclerosis: Competitive Landscape to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3495

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 6990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10485
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Multiple Sclerosis: Competitive Landscape to 2026

Summary

Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS due to a dysfunctional immune system, leading to neurological disability1. The etiology of MS remains unknown; however, it is widely regarded as a complex interaction of genetic susceptibility, dysfunction of the immune system, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of MS. Overall, GlobalData expects that new drug approvals will expand the treatment options and drive MS market growth over the next decade (2016-2026).

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include-

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global MS market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Table Of Content

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

1.4 Upcoming Related Reports 5

2. Executive Summary 6

2.2 Key Findings 7

2.2 Key Events 8

3. Introduction 9

3.1 Report Scope 10

3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

4.1 Pipeline Overview 15

4.2 Pipeline Breakdown by Region/Country 17

4.3 Pipeline Breakdown by Target/MOA 18

4.4 Drug Review Designations 19

4.5 Products in Clinical Development 20

5. Clinical Trial Assessment 22

5.1 Clinical Trials Overview 23

5.2 Top Sponsors of Clinical Trials in Multiple Sclerosis 24

5.3 Trial Breakdown by Region 26

5.4 Therapy Area Perspective 27

5.5 Enrollment Analytics 28

6 Commercial Assessment 31

6.1 Leading Marketed Products 32

6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

7.1 Events Classification Overview 35

7.2 US 36

7.3 5EU 37

7.4 Japan 38

7.5 Canada 39

8 Appendix 40

8.1 Sources 41

8.2 Methodology 43

8.3 Key Events Included in the Analysis 44

8.4 About the Authors 47

8.5 About GlobalData 50

8.6 Disclaimer 52

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Novartis

Biogen

Sanofi

Johnson & Johnson

Teva

Takeda

MedDay

Celgene

AB Science

TG Therapeutics

Biocad

Eisai

Mitsubishi Tanabe

Merck Serono

EMD Serono

Bayer

Roche

Genetech

Cytocom

Asdera

Multiple Sclerosis: Competitive Landscape to 2026

Summary

Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS due to a dysfunctional immune system, leading to neurological disability1. The etiology of MS remains unknown; however, it is widely regarded as a complex interaction of genetic susceptibility, dysfunction of the immune system, and environmental factors.

This report provides an assessment of the pipeline, clinical, and commercial landscape of MS. Overall, GlobalData expects that new drug approvals will expand the treatment options and drive MS market growth over the next decade (2016-2026).

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include-

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global MS market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

1.4 Upcoming Related Reports 5

2. Executive Summary 6

2.2 Key Findings 7

2.2 Key Events 8

3. Introduction 9

3.1 Report Scope 10

3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

4.1 Pipeline Overview 15

4.2 Pipeline Breakdown by Region/Country 17

4.3 Pipeline Breakdown by Target/MOA 18

4.4 Drug Review Designations 19

4.5 Products in Clinical Development 20

5. Clinical Trial Assessment 22

5.1 Clinical Trials Overview 23

5.2 Top Sponsors of Clinical Trials in Multiple Sclerosis 24

5.3 Trial Breakdown by Region 26

5.4 Therapy Area Perspective 27

5.5 Enrollment Analytics 28

6 Commercial Assessment 31

6.1 Leading Marketed Products 32

6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

7.1 Events Classification Overview 35

7.2 US 36

7.3 5EU 37

7.4 Japan 38

7.5 Canada 39

8 Appendix 40

8.1 Sources 41

8.2 Methodology 43

8.3 Key Events Included in the Analysis 44

8.4 About the Authors 47

8.5 About GlobalData 50

8.6 Disclaimer 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Novartis

Biogen

Sanofi

Johnson & Johnson

Teva

Takeda

MedDay

Celgene

AB Science

TG Therapeutics

Biocad

Eisai

Mitsubishi Tanabe

Merck Serono

EMD Serono

Bayer

Roche

Genetech

Cytocom

Asdera